Study Details

Back to Search Results

An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Recruitment complete
The study is ongoing, and participants are receiving an intervention or being examined, but potential participants are not currently being recruited or enrolled.

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT04076059

Astellas Study ID

The unique identification code given by the study sponsor.

9785-CL-0336

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Prostate Cancer

Phase

These clinical trials are done to confirm that an experimental treatment helps participants who have a specific condition. These clinical trials often compare the experimental treatment to another treatment or, if appropriate, a placebo.

Phase 3

Age

18 Years - N/A

Sex

Male

Product

enzalutamide

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Sep 2019 - Oct 2025

Masking

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Enrollment number

180

China ARCHES: A Multicenter, Phase 3, Randomized, Double-blind, Placebo controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Study summary

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site CN86003

Shanghai, China

Site CN86026

Wuhan, China

Site CN86013

Shanghai, China

Site CN86004

Nanchang, China

Site CN86025

Fuzhou, China

Site CN86020

Shenyang, China

Site CN86035

Beijing, China

Site CN86011

Shenzhen, China

Site CN86030

Qingdao, China

Site CN86001

Guangzhou, China

Site CN86016

Changsha, China

Site CN86014

Shanghai, China

Site CN86029

Zhengzhou, China

Site CN86032

Suzhou, China

Site CN86005

Wulumuqi, China

Site CN86017

Zhengzhou, China

Site CN86028

Hangzhou, China

Site CN86012

Tianjin, China

Site CN86036

Hangzhou, China

Site CN86023

Changsha, China

Site CN86019

Wuhan, China

Site CN86022

Beijing, China

Site CN86010

Shanghai, China

Site CN86027

Shanghai, China

Site CN86021

Wuxi, China

Site CN86009

Changsha, China

Site CN86002

Shanghai, China

Site CN86038

Xi'an, China

Site CN86031

Shenzhen, China

Site CN86024

Changchun, China

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo